Compare ARK Genomic Revolution ETF (ARKG) vs Docusign Inc (DOCU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Docusign Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.8, while Docusign Inc trades at $50.33 (market cap $9.39B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Docusign Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | DOCU | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $85.01 |
52-Week Low | $23.09 | $41.75 |
Market Cap | — | $9.39B |
Enterprise Value | — | $8.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
DOCU trades at $49.18, up 0.86% today, with a bullish technical signal from moving averages and strong support near $47. The company reported Q1 2026 EPS of $1.09, beating estimates, and maintains robust gross margins of 79.4%. Recent partnerships with Perplexity and Slack highlight growth in intelligent agreement management, while revenue guidance for 2026 stands at $3.3 billion.
Outlook remains positive with a consensus price target of $55.40, though high valuation multiples (P/E 31.94) and overbought RSI levels pose near-term risks. Competitive pressures in SaaS and reliance on subscription growth are key watchpoints for investors seeking exposure to DOCU's profitable expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →
